BofA lowered the firm’s price target on Regeneron (REGN) to $535 from $547 and keeps an Underperform rating on the shares. Total revenues came in light as Eylea again disappointed in Q1, the analyst tells investors. For 2025, the firm’s total revenues and EPS estimates decrease by low/mid-single digit percentages after lowering Eylea HD estimates, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron announces 24 abstract on Dupixent clinical data
- Regeneron price target lowered to $810 from $940 at Guggenheim
- Regeneron: Strong Growth Potential and Innovation Commitment Amidst Challenges
- Regeneron price target lowered to $940 from $975 at Truist
- Regeneron price target lowered to $943 from $1,051 at RBC Capital